D Anzalone
Overview
Explore the profile of D Anzalone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Groutz A, Blaivas J, Chaikin D, Resnick N, Engleman K, Anzalone D, et al.
J Urol
. 2000 Aug;
164(3 Pt 1):698-701.
PMID: 10953128
Purpose: We assessed the test-retest reliability of a 24, 48 and 72-hour micturition diary and pad test in patients referred for the evaluation of urinary incontinence and lower urinary tract...
2.
Werch C, Anzalone D, Carlson J, Brokiewicz L, Felker J
J Sch Health
. 1995 Sep;
65(7):255-9.
PMID: 8569204
This study explored stages of alcohol acquisition and risk-factors associated with stages based on the Multi-Component Motivational Stages model. Two hundred fifty-four sixth-eighth grade students from an urban school completed...
3.
Falkner B, Canessa M, Anzalone D
Am J Hypertens
. 1995 May;
8(5 Pt 1):454-60.
PMID: 7662220
The purpose of this study was to determine whether antihypertensive therapy with the angiotensin converting enzyme inhibitor lisinopril would alter cell Na+ transport kinetics, metabolic parameters associated with insulin resistance,...
4.
Werch C, Anzalone D
J Drug Educ
. 1995 Jan;
25(2):81-98.
PMID: 7658298
The purpose of this article was to examine the conceptual and empirical foundations of individual drug use stage development and progression related to tobacco, alcohol, and drugs. This review indicated...
5.
Weir M, Fagan T, Chrysant S, Flamenbaum W, Kaihlanen P, Lueg M, et al.
J Hum Hypertens
. 1994 Jul;
8(7):531-7.
PMID: 7932518
One hundred and ten patients (mean age 50.6 years) with moderate to severe essential hypertension (DBP between 105 and 116 mmHg) were randomised to eight weeks of double-blind treatment with...